Clarivate Epidemiology's coverage of T2D comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of T2D for…
Clarivate Epidemiology's coverage of Sandhoff disease comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France,…
Rheumatoid arthritis (RA) patients who are refractory to one or more tumor necrosis factor-alpha (TNF-α) inhibitors are generally prescribed a non-TNF-targeted therapy (e.g., Bristol Myers Squibb…
Although Ofev and Esbriet are welcome options in the treatment armamentarium for idiopathic pulmonary fibrosis (IPF), therapies that can further delay or reverse the disease’s progression,…
Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s…
The drug market for chronic spontaneous urticaria (CSU; previously known as chronic idiopathic urticaria) is dominated by oral medications, including those approved (e.g., first- and second-…
Although Ofev and Esbriet are welcome options in the treatment armamentarium for idiopathic pulmonary fibrosis (IPF), therapies that can further delay or reverse the disease’s progression,…
The drug market for chronic spontaneous urticaria (CSU; previously known as chronic idiopathic urticaria) is dominated by oral medications, including those approved (e.g., first- and second-…
Rheumatoid arthritis (RA) patients who are refractory to one or more tumor necrosis factor-alpha (TNF-α) inhibitors are generally prescribed a non-TNF-targeted therapy (e.g., Bristol Myers Squibb…
Rheumatoid arthritis (RA) treatment is typically initiated with cost-effective conventional DMARDs (cDMARDs), such as methotrexate or hydroxychloroquine. For patients who fail cDMARD treatment or…
MARKET OUTLOOK Parkinson’s disease (PD) is a progressive neurodegenerative condition that is treated chronically with prescription therapies from an array of mechanistically distinct drug…
Scleroderma (systemic sclerosis [SSc]) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
MARKET OUTLOOK Intensive insulin regimens have been shown to delay the progression of complications associated with untreated or poorly treated type 1 diabetes (T1D). Therefore, it is unsurprising…
Scleroderma (systemic sclerosis [SSc]) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
MARKET OUTLOOK Age-related macular degeneration (AMD) is a leading cause of visual impairment in the United States, and more than half of advanced AMD patients have the wet (exudative, neovascular…